secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001214659-24-008531
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro terminates ATM equity program after raising ~$1.3M at ~$1.20/share
--------------------------------------------------------------------------------

- Terminated ATM agreement with Ascendiant Capital Markets effective May 16, 2024.
- Sold 1,076,821 shares and raised approximately $1.3 million in gross proceeds (~$1.20 per share).
- Company cited limiting uncertainty and unfavorable dilution for stockholders as reason for termination.
- No further sales will be made under the ATM facility; all obligations cease upon termination.
- Clinical-stage biotech focused on Alzheimer's, bipolar, MDD, and PTSD treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924008531/0001214659-24-008531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924008531/o572478k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-008531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer